Silence Therapeutics (NASDAQ:SLN) Given New $45.00 Price Target at Morgan Stanley

Silence Therapeutics (NASDAQ:SLN) had its target price cut by Morgan Stanley from $49.00 to $45.00 in a research note released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities analysts also recently issued research reports about the company. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. The Goldman Sachs Group decreased their target price on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research report on Tuesday. BMO Capital Markets decreased their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday. Chardan Capital reaffirmed a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a research report on Tuesday, December 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, January 29th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Silence Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

Silence Therapeutics Trading Up 2.3 %

Silence Therapeutics stock opened at $4.85 on Wednesday. Silence Therapeutics has a 12 month low of $4.06 and a 12 month high of $27.72. The stock’s 50 day moving average is $5.44 and its 200-day moving average is $11.48. The company has a market capitalization of $145.16 million, a price-to-earnings ratio of -3.09 and a beta of 1.08.

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors have recently made changes to their positions in SLN. JPMorgan Chase & Co. bought a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $26,000. GAMMA Investing LLC lifted its stake in Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after purchasing an additional 5,233 shares during the last quarter. Barclays PLC lifted its stake in Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after purchasing an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Silence Therapeutics during the fourth quarter worth $69,000. Finally, Virtus ETF Advisers LLC lifted its stake in Silence Therapeutics by 130.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock worth $74,000 after purchasing an additional 6,098 shares during the last quarter. 98.73% of the stock is currently owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.